NY-AQARA
Aqara, a leading provider of smart home solutions, is excited to initiate the crowdfunding campaign for its latest home access solution, the Smart Lock U200, on Kickstarter. Designed for flexibility, convenience and security, the U200 lock is built upon the latest Thread protocol and natively Matter-enabled, aiming for effortless integration with the widest range of smart home devices across systems and brands1.
At its core, the Aqara U200 utilizes modern engineering crafted to provide users with numerous secure access options, ranging from fingerprints, one-time and recurring PIN codes, remote access via mobile apps, voice assistant commands to Aqara NFC cards and physical keys. Aqara is also working to add the HomeKey support to the U200 lock, which allows iOS users to unlock by simply tapping a compatible iPhone and Apple Watch. The U200 will be one of the first Matter-compatible locks to support HomeKey unlocking, and the Aqara team is sparing no time on developing and testing before delivering the optimized experiences2.
The U200 features a retrofit design, allowing for hassle-free installation on existing doors - without the need for extensive modification or renovation. Compatible with most doors in both Europe and North America, it attaches to existing lock mechanisms such as European cylinders (emergency function required) and deadbolts using one of the provided adapters3. The U200 intends to bring the modern keyless lifestyle to a broad array of homeowners and renters, while preserving the option to use traditional keys. Users also enjoy easy access sharing, remote access control, and real-time lock status updates for enhanced convenience and security.
The U200 lock runs on rechargeable Li-Ion batteries, while its wireless keypad can either be powered by a pack of four AAA batteries or wired to the existing doorbell wire (12V-24V DC power supply). Thanks to the power-efficient Thread protocol, the U200 lock features a battery life of up to 6 months between each charge4. Moreover, the wireless keypad boasts an IPX5 rating and withstands extreme heat and cold (-18℃/0℉ to 66℃/151℉), ensuring endurance under any climate.
As an integral part of a connected home, the U200 smart lock seamlessly works with other smart home accessories, allowing users to create a fully automated and customized smart home experience. For example, to disarm the home security system automatically when the U200 is unlocked by a family member, or to activate the indoor camera and the video doorbell after consecutive failed attempts to unlock the door. With three color options available for pre-order on Kickstarter, the U200 can fit into most home decor, making it the perfect addition to any home.
The Aqara Smart Lock U200 is now available for pre-order on Kickstarter at https://www.kickstarter.com/projects/aqara-u200/smartlock for those looking to be among the first to explore the latest in home access technologies.
- The U200 can be paired to the Aqara Home app using Bluetooth or the upcoming Aqara Hub M3. Compatibility with third-party Matter-enabled platforms (e.g., Amazon Alexa, Apple Home, Google Home, Samsung SmartThings, Home Assistant) is expected to roll out in waves, and may not be available by the shipment of pre-ordered units.
- HomeKey unlocking support is currently under development, and is expected to become available via a subsequent OTA update after the lock receives certain certification.
- Limitation applies. Please check the Kickstarter page or consult Aqara support for detailed guidelines on the U200 lock compatibility.
- The 6-month battery life is based on the assumption of 8 cycles of fingerprint/NFC unlocking and locking per day.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227373928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom